XML 32 R23.htm IDEA: XBRL DOCUMENT

Revenues (Tables)

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):



		Three months ended March 31,
		2019												2018
		US				ROW				Total				US				ROW				Total
Enbrel^®(etanercept)		$	1,106			$	45			$	1,151			$	1,050			$	55			$	1,105
Neulasta^®(pegfilgrastim)		893				128				1,021				1,009				146				1,155
Prolia^®(denosumab)		390				202				592				320				174				494
XGEVA^® (denosumab)		356				115				471				332				113				445
Aranesp^®(darbepoetin alfa)		182				232				414				225				229				454
KYPROLIS^®(carfilzomib)		154				91				245				137				85				222
EPOGEN^®(epoetin alfa)		219				—				219				244				—				244
Sensipar^®/Mimpara^®(cinacalcet)		135				78				213				409				88				497
Other products		556				404				960				421				306				727
Total product sales⁽¹⁾		$	3,991			$	1,295			5,286				$	4,147			$	1,196			5,343
Other revenues										271												211
Total revenues										$	5,557											$	5,554

^____________


⁽¹⁾	Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2019 and 2018.